ALZNAlzamend Neuro, Inc.同业对比
Alzamend Neuro, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALZN本股 | $9M#8 | — | 1.5x#11 | — | — | -94.3%#14 | — | -151.2%#8 | — | — | -30.0%#2 | — |
| TOVX | $10M#2 | 0.2x#3 | 0.2x#1 | — | -100.0%#5 | 7.5%#5 | — | -42.1%#4 | -51.4%#1 | — | — | — |
| PPCB | $37M#1 | 0.0x#1 | 3.7x#13 | — | — | -3136.6%#15 | — | -599.6%#14 | -533.3%#3 | — | -98.8%#12 | — |
| KALA | $10M#4 | 0.0x#2 | 1.1x#7 | — | — | 29.9%#4 | — | -298.3%#11 | -69.9%#2 | — | -99.9%#13 | — |
| AZTR | $10M#5 | 8.1x#5 | 1.3x#10 | — | -100.0%#5 | -22.2%#9 | — | -149.4%#7 | — | — | — | — |
| FBLG | $10M#6 | 0.5x#4 | 2.1x#12 | — | — | -67.1%#13 | — | -402.2%#12 | -1409.7%#5 | — | — | — |
| VTGN | $10M#3 | — | 0.4x#3 | 8.0x#3 | 161.1%#2 | -35.5%#12 | -5683.7%#4 | -284.7%#10 | -949.7%#4 | — | -92.1%#11 | — |
| APRE | $9M#7 | — | 0.2x#2 | — | — | 2.8%#7 | — | -32.8%#3 | — | — | -50.0%#3 | — |
| ENSC | $9M#10 | — | — | 1.7x#1 | -2.8%#3 | -27.4%#10 | -202.1%#1 | — | — | — | -78.8%#9 | — |
| BFRG | $9M#11 | — | 1.2x#9 | 74.9x#5 | — | 7.1%#6 | -5652.4%#3 | -93.0%#5 | -5287.3%#6 | — | -66.6%#5 | — |
| CNSP | $9M#12 | — | 0.5x#4 | — | — | -7.6%#8 | — | -0.1%#2 | — | — | -24.5%#1 | — |
| XCUR | $9M#9 | — | 9.0x#14 | — | -100.0%#5 | 49.0%#2 | — | -506.2%#13 | — | — | -64.6%#4 | — |
| TRAW | $8M#13 | — | 0.7x#5 | 2.9x#2 | 1134.5%#1 | 105.5%#1 | -640.7%#2 | 79.2%#1 | — | — | -75.7%#8 | — |
| SNGX | $8M#14 | — | 1.2x#8 | 65.8x#4 | -85.8%#4 | -33.7%#11 | -9923.2%#5 | -167.0%#9 | — | 5#1 | -87.0%#10 | — |
| IMNN | $8M#15 | — | — | — | — | — | — | — | — | — | -74.4%#7 | — |
| ACXP | $7M#16 | — | 0.9x#6 | — | — | 43.5%#3 | — | -97.7%#6 | — | — | -66.6%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议